The proto-oncogene Pim-1 is a target of miR-33a
- PMID: 21743487
- DOI: 10.1038/onc.2011.278
The proto-oncogene Pim-1 is a target of miR-33a
Abstract
The constitutively active serine/threonine kinase Pim-1 is upregulated in different cancer types, mainly based on the action of several interleukines and growth factors at the transcriptional level. So far, a regulation of oncogenic Pim-1 by microRNAs (miRNAs) has not been reported. Here, we newly establish miR-33a as a miRNA with potential tumor suppressor activity, acting through inhibition of Pim-1. A screen for miRNA expression in K562 lymphoma, LS174T colon carcinoma and several other cell lines revealed generally low endogenous miR-33a levels relative to other miRNAs. Transfection of K562 and LS174T cells with a miR-33a mimic reduced Pim-1 levels substantially. In contrast, the cell-cycle regulator cyclin-dependent kinase 6 predicted to be a conserved miR-33a target, was not downregulated by the miR-33a mimic. Seed mutagenesis of the Pim-1 3'-untranslated region in a luciferase reporter construct and in a Pim-1 cDNA expressed in Pim-1-deficient Skov-3 cells demonstrated specific and direct downregulation of Pim-1 by the miR-33a mimic. The persistence of this effect was comparable to that of a small interfering RNA-mediated knockdown of Pim-1, resulting in decelerated cell proliferation. In conclusion, we demonstrate the potential of miR-33a to act as a tumor suppressor miRNA, which suggests miR-33a replacement therapy through delivery of miR mimics as a novel therapeutic strategy.
Similar articles
-
Antiproliferative potential of miR-33a in laryngeal cancer Hep-2 cells via targeting PIM1.Head Neck. 2018 Nov;40(11):2455-2461. doi: 10.1002/hed.25361. Epub 2018 Aug 13. Head Neck. 2018. PMID: 30102806
-
MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma.Cancer Res. 2011 Aug 1;71(15):5214-24. doi: 10.1158/0008-5472.CAN-10-4645. Epub 2011 Jun 20. Cancer Res. 2011. PMID: 21690566
-
MiR-377 inhibits the proliferation of pancreatic cancer by targeting Pim-3.Tumour Biol. 2016 Nov;37(11):14813-14824. doi: 10.1007/s13277-016-5295-4. Epub 2016 Sep 16. Tumour Biol. 2016. PMID: 27638830
-
MicroRNA-33a/b in lipid metabolism – novel “thrifty” models.Circ J. 2015;79(2):278-84. doi: 10.1253/circj.CJ-14-1252. Epub 2015 Jan 8. Circ J. 2015. PMID: 25744742 Review.
-
Understanding the functional discrepancy of Pim-1 in cancer.Front Biosci (Elite Ed). 2015 Jan 1;7(2):208-14. doi: 10.2741/E728. Front Biosci (Elite Ed). 2015. PMID: 25553374 Review.
Cited by
-
Analysis of transcriptional regulation of the human miR-17-92 cluster; evidence for involvement of Pim-1.Int J Mol Sci. 2013 Jun 7;14(6):12273-96. doi: 10.3390/ijms140612273. Int J Mol Sci. 2013. PMID: 23749113 Free PMC article.
-
Functional role and therapeutic potential of the pim-1 kinase in colon carcinoma.Neoplasia. 2013 Jul;15(7):783-94. doi: 10.1593/neo.13172. Neoplasia. 2013. PMID: 23814490 Free PMC article.
-
Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials.Sci Transl Med. 2019 Sep 11;11(509):eaaw8412. doi: 10.1126/scitranslmed.aaw8412. Sci Transl Med. 2019. PMID: 31511426 Free PMC article.
-
The Mammalian response to virus infection is independent of small RNA silencing.Cell Rep. 2014 Jul 10;8(1):114-25. doi: 10.1016/j.celrep.2014.05.038. Epub 2014 Jun 19. Cell Rep. 2014. PMID: 24953656 Free PMC article.
-
Pathophysiological roles of Pim-3 kinase in pancreatic cancer development and progression.World J Gastroenterol. 2014 Jul 28;20(28):9392-404. doi: 10.3748/wjg.v20.i28.9392. World J Gastroenterol. 2014. PMID: 25071334 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources